-
Product Name
Anti-CXCL9 / MIG antibody
- Documents
-
Description
Rabbit polyclonal to CXCL9 / MIG
-
Tested applications
ELISA, WB
-
Species reactivity
Human CXCL9 / MIG
-
Alternative names
CMK antibody; crg-10 antibody; crg-10 antibody; Cxcl9 antibody; CXCL9 antibody; Humig antibody; Mig antibody; MIG antibody; MuMIG antibody; Scyb9 antibody; SCYB9 antibody; CMK antibody; MIG antibody; Humig antibody; SCYB9 antibody; crg-10 antibody; CMK antibody; Mig antibody; MuMIG antibody; Scyb9 antibody; crg-10 antibody; BB139920 antibody; BB139920 antibody; CMK antibody
- Immunogen
-
Isotype
Rabbit IgG
-
Preparation
Produced in rabbits immunized with purified, recombinant Human CXCL9 / MIG (rh CXCL9 / MIG; Q07325; Thr 23-Thr 125). CXCL9 / MIG specific IgG was purified by Human CXCL9 / MIG affinity chromatography.
-
Clonality
Polyclonal
-
Formulation
0.2 μm filtered solution in PBS with 5% trehalose
-
Storage instructions
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. -
Applications
WB: 5-10 μg/mL
ELISA: 0.1-0.2 μg/mL
This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human CXCL9. The detection limit for Human CXCL9 is approximately 0.00975 ng/well.
-
Validations
CXCL9 / MIG Antibody, Rabbit PAb, Antigen Affinity Purified, Western blot
-
Background
Chemokine (C-X-C motif) ligand 9 (CXCL9), also known as Monokine induced by gamma interferon (MIG), is a small cytokine belonging to the CXC chemokine family. The function of this chemokine has not been specifically defined; however, it is thought to be involved in T cell trafficking. CXCL9/MIG functions as one of the three ligands of chemokine receptor CXCR3 which is a G protein-coupled receptor found predominantly on T cells. CXCL9/MIG, together with CXCL10 and CXCL11, may activate CXCR3 by binding to it. CXCL9 serves as a cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory response. It has been observed that tumour endothelial cells secrete high levels of CXCL9 in all, and CXCL10 in most melanoma metastases. Experiment data represent novel mechanisms by which tumour cells in melanoma metastases might use the chemokine-expressing endothelium to leave the tumour and eventually to form additional metastases at distinct sites. Experiment results also improved that CXCL9/MIG plays an important role in CD4+ T lymphocyte recruitment and development of CAV, MOMA-2+ macrophages are the predominant recipient-derived source of CXCL9/MIG, and recipient CD4 lymphocytes are necessary for sustained CXCL9/MIG production and CAV development in this model. Neutralization of the chemokine CXCL9/MIG may have therapeutic potential for the treatment of chronic rejection after heart transplantation.
-
References
- Ruehlmann JM, et al. (2001) MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res. 61(23): 8498-503.
- Belperio JA, et al. (2003) Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. J Immunol. 171(9): 4844-52.
- Colvin RA, et al. (2004) Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem. 279(29): 30219-27.
- Valbuena G, et al. (2003) Expression analysis of the T-cell-targeting chemokines CXCL9 and CXCL10 in mice and humans with endothelial infections caused by rickettsiae of the spotted fever group. Am J Pathol. 163(4): 1357-69.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"